Efficacy of Routine Fecal Microbiota Transplantation for Treatment of Recurrent Clostridium difficile Infection: A Retrospective Cohort Study

Table 1

Clinical characteristics of the patients.

	All	Success	Failure	value
Number of patients	47	32	15	—
Age
Median, years (range)	70 (25–95)	69.5 (25–90)	74 (40–95)	n.s.
Gender
Female, n (%)	33 (70)	20 (61)	13 (39)	n.s.
Male, n (%)	14 (30)	12 (86)	2 (14)
Recurrent CDI, n (%)
1-2	13 (27)	9 (28)	4 (26)	n.s.
3 or more	34 (73)	23 (72)	11 (74)
Antibiotics regimes 90 days prior to the first CDI
No, n (%)	8 (17)	7 (87.5)	1 (12.5)	n.s.
Yes, n (%)	39 (83)	25 (64)	14 (36)
Days of antibiotics 90 days prior to CDI
0 (%)	8 (17)	7 (87.5)	1 (12.5)	n.s.
1–10 (%)	15 (33)	9 (60)	6 (40)
>11–20 (%)	23 (50)	15 (65)	8 (35)
Reported use of PPI at CDI diagnosis (%)
Yes	25 (53)	16 (64)	9 (36)	n.s.
No	22 (47)	16 (73)	6 (27)
Days of hospitalization 90 days prior to CDI
0 (%)	24 (52)	17 (71)	7 (29)	—
1–10 (%)	10 (22)	7 (70)	3 (30)
>11–20 (%)	12 (26)	7 (58)	5 (42)
Known GI surgery prior to CDI (%)
Yes	16 (34)	13 (81)	3 (19)	—
No	31 (66)	19 (61)	12 (39)
Kidney function at CDI (eGFR), n (%)
>90	10 (22)	9 (90)	1 (10)	—
60–89	19 (40)	12 (63)	7 (37)
HD and PD < 15–59	18 (38)	11 (61)	7 (39)
Feces type (%)
Culture no.	14 (30)	9 (64)	5 (36)	—
Donor no.	33 (70)	23 (70)	10 (30)
Karnofsky performance status
Median (range)	80 (40–100)	90 (50–100)	70 (40–100)
No. of comorbidities (%)
0-1	14 (30)	11 (78)	3 (21)	—
2-3	23 (49)	14 (61)	9 (39)
>4	10 (21)	7 (70)	3 (30)
Days to first FMT
Median	144	155.5	138	—
Range	9–884	9–884	40–337

Data based on 46 of 47 individuals; value <0.05 was considered as significant; n.s.: not significant.